Tetratherix Limited (ASX: TTX) — Perfil da empresa, notícias e dados financeiros
Tetratherix Limited is a regenerative medicine and medical technology company focused on developing injectable bioresorbable polymer platforms for soft and hard tissue applications.
Tetratherix Limited
Tetratherix Limited is a regenerative medicine and medical technology company focused on developing injectable bioresorbable polymer platforms for soft and hard tissue applications. Its proprietary fluid technology transitions at body temperature into a three-dimensional tissue-adhesional matrix, enabling minimally invasive delivery via injection or spray. The company targets key clinical areas including dental and orthopaedic bone regeneration, surgical soft tissue healing, tissue spacing for radiation therapy and ophthalmic procedures, and sprayable intranasal drug delivery systems. Operating in Australia, the firm partners with global healthcare companies to co-develop, scale, and manufacture commercial biomaterial products.
Resumo
Operações
Produtos e/ou serviços de Tetratherix Limited
- Bone Regeneration Matrix: Flowable biomaterial bone extenders designed for dental and orthopaedic applications. Applied as an injectable fluid, the material transitions at body temperature into a three-dimensional scaffold supporting natural cellular infiltration and bone structural tissue integration.
- Soft Tissue Healing Hydrogels: Synthetic biomimetic matrices formulated to physically integrate with host tissue across surgical incision sites, spinal interventions, cartilage repair, and tendon treatments, creating structural bridges that facilitate cell migration and natural tissue restoration without permanent synthetic residue.
- Surgical Space Maintenance Systems: Injectable tissue spacing hydrogels engineered to establish and maintain surgical space during complex interventional procedures. The resorbable formulations remain visible under medical imaging to support procedural accuracy, radiation oncology targeting, and ophthalmic cataract surgeries.
- Intranasal Precision Drug Delivery: Sprayable intranasal drug delivery technology engineered to form a localized mucoadhesive hydrogel coating within the nasal cavity, protecting sensitive active pharmaceutical ingredients while providing sustained transmucosal absorption into systemic circulation.
- Temperature-Responsive Biomaterial Platform: Core bioresorbable fluid technology that converts from a liquid state into a tissue-adhesive scaffold upon exposure to physiological body temperature, enabling minimally invasive administration via injection or spray across diverse anatomical locations.
- Medical Device Partnering and Manufacturing: Staged collaborative development and contract manufacturing operations providing feasibility assessment, custom formulation, clinical translation, and scalable manufacturing of injectable hydrogel products for international healthcare and pharmaceutical distribution partners.
equipe executiva do Tetratherix Limited
- William Anthony KnoxCEO, MD & Executive Director
- Ali FathiFounder, CTO & Executive Director
- Terence AbramsFounder & COO
- Cherie BeachChief Financial Officer
- Jacob PfefferChief of Staff, General Counsel & Company Secretary
- Alex WashingtonFinancial Controller
Últimas notícias sobre a Tetratherix Limited
Comunicados recentes
O que a Tetratherix Limited (TTX) comunicou ao mercado, do mais recente para o mais antigo.
- Notice of Annual General Meeting/Proxy Form
- Application for quotation of securities - TTX
- Tegenix FDA Review Progress
- Notification regarding unquoted securities - TTX
- SPP Results
- Application for quotation of securities - TTX
Principais indicadores financeiros
Resultados divulgados pela Tetratherix Limited, em AUD.
- Cap. de mercado
- 292,1 mi
- Receita (TTM)
- 3,9 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.2
- Dividend yield
- —
- Margem de lucro
- -241.4%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 918,2 mil | -12,5 mi | -9,3 mi | |
| 1,1 mi | -9,3 mi | -9,4 mi | |
| 863,7 mil | -2,4 mi | -2,6 mi | |
| 566,3 mil | -1,7 mi | -1,8 mi |